Literature DB >> 7460018

Transcripts from the adenovirus-2 major late promoter yield a single early family of 3' coterminal mRNAs and five late families.

A R Shaw, E B Ziff.   

Abstract

The major late promoter of adeovirus-2 is located at coordinate 16.45 and initiates synthesis of nuclear precursors that are processed into mRNAs which fall into five 3- co-terminal families, L1-L5. These mRNAs all share a common tripartite 5' leader with a capped terminus encoded at th RNA initiation site. We show that the coorindate 16.45 RNA initiation site is also an early promoter, and yields transcripts detectable as early as 1 hr post-infection, prior to DNA replication and the early-late switch at 6-8 hr. Polyadenylated cytoplasmic RNA from the first 3- co-terminal family, L1, is also produced from the earliest stages of infection. L1 mRNA accumulates in the cytoplasm in the presence of cycloheximide, which blocks DNA replication and the onset of the late phase. Early nuclear RNA contains the same capped 5' terminal RNAase T-1 undecanucleotide and promoter proximal oligonucleotides present in late transcripts. This implies that precisely the same transcription start site is utilized for early L1 mRNA synthesis as is used during the late stage for L1-L5 late mRNA synthesis. In contrast to the early apperance of L1 mRNA, neither L2 nor L3 mRNAs are detected until 5-6 hr post infection. We cnclude that a major event in the Ad-2 early-late switch is a novel form of control which activates L2-L5 mRNA production.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7460018     DOI: 10.1016/0092-8674(80)90568-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  92 in total

1.  Regulated adenovirus mRNA 3'-end formation in a coupled in vitro transcription-processing system.

Authors:  S I Wilson-Gunn; J E Kilpatrick; M J Imperiale
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

2.  The 11,600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection.

Authors:  A E Tollefson; A Scaria; S K Saha; W S Wold
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

3.  The downstream regulatory sequence of the adenovirus type 2 major late promoter is functionally redundant.

Authors:  X C Li; W L Huang; S J Flint
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

4.  Identification of a novel downstream binding protein implicated in late-phase-specific activation of the adenovirus major late promotor.

Authors:  G Mondesert; C Tribouley; C Kedinger
Journal:  Nucleic Acids Res       Date:  1992-08-11       Impact factor: 16.971

5.  Adenovirus late-phase infection is controlled by a novel L4 promoter.

Authors:  Susan J Morris; Gillian E Scott; Keith N Leppard
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

Review 6.  Viral and cellular interactions during adenovirus DNA replication.

Authors:  Matthew Charman; Christin Herrmann; Matthew D Weitzman
Journal:  FEBS Lett       Date:  2019-12-17       Impact factor: 4.124

7.  Viral DNA synthesis-dependent titration of a cellular repressor activates transcription of the human adenovirus type 2 IVa2 gene.

Authors:  C Iftode; S J Flint
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-09       Impact factor: 11.205

8.  Dependence of the encapsidation function of the adenovirus L1 52/55-kilodalton protein on its ability to bind the packaging sequence.

Authors:  Pilar Perez-Romero; Kurt E Gustin; Michael J Imperiale
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

9.  cis-acting elements and a trans-acting factor affecting alternative splicing of adenovirus L1 transcripts.

Authors:  C Delsert; N Morin; D F Klessig
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

10.  Transcription of adenovirus cores in vitro: major RNA products differ from those made from a DNA template.

Authors:  E Daniell; M J Fedor
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.